person · Reporting owner

AKKARAJU SRINIVAS

Disclosed activity across 16 companies

Tapewire entity: 32933
SEC CIK: 0001253170

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	Director	September 04, 2026	September 10, 2026
Jiya Acquisition Corp.JYAC · Entity 123583	Director · 10% owner	September 23, 2022	September 23, 2022
Kalaris Therapeutics, Inc.KLRS · Entity 6805	Director	June 03, 2026	June 04, 2026
LENZ Therapeutics, Inc.GRPH · Entity 6475	10% owner	April 11, 2022	April 13, 2022
Mineralys Therapeutics, Inc.MLYS · Entity 4432	Director · 10% owner	February 19, 2026	February 21, 2026
Neurogene Inc.NGNE · Entity 5160	10% owner	November 26, 2024	November 27, 2024
Principia Biopharma Inc.PRNB · Entity 146423	Director	September 13, 2018	January 11, 2019
Scholar Rock Holding CorpSRRK · Entity 3721	Director	June 04, 2026	June 08, 2026
Seagen Inc.SGEN · Entity 13956	Director	May 15, 2020	May 19, 2020
Syros Pharmaceuticals, Inc.SYRS · Entity 85437	Director	September 16, 2024	September 18, 2024
aTYR PHARMA INCLIFE · Entity 7233	Director	May 09, 2017	May 11, 2017
vTv Therapeutics Inc.VTVT · Entity 6614	Director	June 26, 2026	June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date September 04, 2026 · Filed September 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	4,937,026	Last balance in matching sequence After 2026-09-08 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-09-04 · Purchase · Acquired 220,070 · Balance 4,711,801 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Row 3 · 2026-09-08 · Sale · Disposed 48,066 · Balance 4,663,735 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Row 5 · 2026-09-08 · Purchase · Acquired 273,291 · Balance 4,937,026 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Samsara Opportunity Fund, L.P.	2,298,783	Last balance in matching sequence After 2026-09-08 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2026-09-04 · Purchase · Acquired 220,070 · Balance 2,073,558 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Row 4 · 2026-09-08 · Sale · Disposed 48,065 · Balance 2,025,493 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Row 6 · 2026-09-08 · Purchase · Acquired 273,290 · Balance 2,298,783 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,553	Reported balance Holding disclosure · report date 2026-09-04 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 3,553

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.

F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

Jiya Acquisition Corp.

Report date September 23, 2022 · Filed September 23, 2022

Jointly reported with Jiya Holding Co LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	2,437,114	Reported balance After 2022-09-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-09-23 · Other · Acquired 29,667 · Balance 2,437,114 F1: The shares of Class B Common Stock of the Issuer ("Class B Shares") will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: Reflects the forfeiture of Class B Shares held by an employee of the Issuer upon such employee's resignation from the Issuer. As a result, these Class B Shares were automatically returned to Jiya Holding Company LLC ("Jiya Holdco") for no consideration ($0). F3: Reflects the Class B Shares held by Jiya Holdco. This amount does not reflect the 30,000 Class B shares directly held by Dr. Srinivas Akkaraju M.D., Ph.D. F4: Jiya HoldCo is wholly owned by Samsara BioCapital, L.P. ("Samsara LP"). Dr. Akkaraju has voting and dispositive control over the reported securities held by Jiya Holdco via Dr. Akkaraju's control of Samsara LP's general partner, Samsara BioCapital GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B Common Stock of the Issuer ("Class B Shares") will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.

F2: Reflects the forfeiture of Class B Shares held by an employee of the Issuer upon such employee's resignation from the Issuer. As a result, these Class B Shares were automatically returned to Jiya Holding Company LLC ("Jiya Holdco") for no consideration ($0).

F3: Reflects the Class B Shares held by Jiya Holdco. This amount does not reflect the 30,000 Class B shares directly held by Dr. Srinivas Akkaraju M.D., Ph.D.

F4: Jiya HoldCo is wholly owned by Samsara BioCapital, L.P. ("Samsara LP"). Dr. Akkaraju has voting and dispositive control over the reported securities held by Jiya Holdco via Dr. Akkaraju's control of Samsara LP's general partner, Samsara BioCapital GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein.

Kalaris Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02	Direct	9,000	Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

LENZ Therapeutics, Inc.

Report date April 11, 2022 · Filed April 13, 2022

Jointly reported with Samsara BioCapital, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	8,459,314	Last balance in matching sequence After 2022-04-12 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2022-04-11 · Purchase · Acquired 74,464 · Balance 8,109,314 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Row 2 · 2022-04-12 · Purchase · Acquired 350,000 · Balance 8,459,314 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy 436, L.P.	37,753	Reported balance Holding disclosure · report date 2022-04-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 37,753 F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.

Mineralys Therapeutics, Inc.

Report date February 19, 2026 · Filed February 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,200	Reported balance After 2026-02-19 transaction · row 1 1 source row Row 1 · 2026-02-19 · Grant · Acquired 6,200 · Balance 6,200 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19	Direct	8,300	Reported balance After 2026-02-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-19 · Grant · Acquired 8,300 · Balance 8,300 F3: The stock option vests in 12 substantially equal monthly installments following the date of grant.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,871,018	Reported balance Holding disclosure · report date 2026-02-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,871,018 F2: Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

F2: Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

F3: The stock option vests in 12 substantially equal monthly installments following the date of grant.

Neurogene Inc.

Report date November 26, 2024 · Filed November 27, 2024

Jointly reported with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	1,717,127	Last balance in matching sequence After 2024-11-26 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2024-11-26 · Purchase · Acquired 20,748 · Balance 1,689,105 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 2 · 2024-11-26 · Purchase · Acquired 10,803 · Balance 1,699,908 F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 3 · 2024-11-26 · Purchase · Acquired 15,219 · Balance 1,715,127 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 4 · 2024-11-26 · Purchase · Acquired 2,000 · Balance 1,717,127 F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

Principia Biopharma Inc.

Report date September 13, 2018 · Filed January 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-09-12	Direct	20,475	Reported balance After 2018-09-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-09-13 · Grant · Acquired 20,475 · Balance 20,475 F1: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Scholar Rock Holding Corp

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,971	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 6,839 · Balance 27,971 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2: Consists of 21,132 shares of common stock and 6,839 RSUs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.33 · Expires 2036-06-04	Direct	4,310	Reported balance After 2026-06-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-04 · Grant · Acquired 4,310 · Balance 4,310 F5: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date.
Common StockSEC Table I · non-derivative	IndirectBy Samsara Opportunity Fund, L.P.	530,038	Reported balance Holding disclosure · report date 2026-06-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 530,038 F3: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	6,367,614	Reported balance Holding disclosure · report date 2026-06-04 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 6,367,614 F4: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.

F2: Consists of 21,132 shares of common stock and 6,839 RSUs.

F3: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

F4: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

F5: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date.

Seagen Inc.

Report date May 15, 2020 · Filed May 19, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	41,503	Reported balance After 2020-05-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-15 · Grant · Acquired 1,335 · Balance 41,503 F1: These restricted stock units will be settled in common stock upon vesting. F2: These restricted stock units shall vest in full on May 15, 2021. F3: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15	Direct	3,171	Reported balance After 2020-05-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-05-15 · Grant · Acquired 3,171 · Balance 3,171

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units will be settled in common stock upon vesting.

F2: These restricted stock units shall vest in full on May 15, 2021.

F3: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

Syros Pharmaceuticals, Inc.

Report date September 16, 2024 · Filed September 18, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,333	Reported balance After 2024-09-16 transaction · row 1 1 source row Row 1 · 2024-09-16 · Exercise / conversion · Acquired 2,667 · Balance 9,333 F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,667	Reported balance After 2024-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-09-16 · Exercise / conversion · Disposed 2,667 · Balance 2,667 F2: Each RSU represents the contingent right to receive one share of the issuer's common stock. F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award.

F2: Each RSU represents the contingent right to receive one share of the issuer's common stock.

F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

aTYR PHARMA INC

Report date May 09, 2017 · Filed May 11, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2027-05-09	Direct	20,000	Reported balance After 2017-05-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-09 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.

vTv Therapeutics Inc.

Report date June 26, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26	Direct	16,983	Reported balance After 2026-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 16,983 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aravive, Inc.

Report date April 08, 2020 · Filed April 09, 2020

Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

CARGO Therapeutics, Inc.

Report date May 30, 2024 · Filed June 04, 2024

Jointly reported with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P.

Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	4,415,689	Reported balance After 2024-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-05-30 · Purchase · Acquired 294,000 · Balance 4,415,689 F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-11 transaction · row 1 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 3,300 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	Reported balance After 2023-08-11 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 5,161,888 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05	Direct	Reported balance After 2023-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F3: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03	Direct	Reported balance After 2023-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25	Direct	Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.

F3: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2023-11-08 · Other · Disposed 37,887 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-11-08 · Other · Disposed 640,688 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08	Direct	Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82	Direct	Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17	Direct	Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $210.36	Direct	Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-08 · Disposition to issuer · Disposed 275 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62	Direct	Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-08 · Disposition to issuer · Disposed 1,750 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22	Direct	Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01	Direct	Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12	Direct	Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25	Direct	Reported balance After 2023-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74	Direct	Reported balance After 2023-11-08 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.

F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 08, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	273,290	$10.63	$2,904,280.16	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 6 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,298,783 F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 08, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	273,291	$10.63	$2,904,290.79	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 5 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,937,026 F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
September 08, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	SaleCommon Stock	48,065	$10.55	$507,008.85	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,025,493 F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 08, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	SaleCommon Stock	48,066	$10.55	$507,019.39	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,663,735 F4 · kind: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
September 04, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	220,070	$11.17	$2,458,842.11	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,073,558 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 04, 2026 Filed Sep 10, 2026 01:39 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	220,070	$11.17	$2,458,842.11	Disclosure SEC source: 0001231919-26-001158 · form4-09102026_010944.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,711,801 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
June 30, 2026 Filed Jul 2, 2026 22:22 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	15,528	$0.00 Strike: $28.14	$0.00	Disclosure SEC source: 0001253170-26-000011 · form4-07022026_100705.xml · derivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,528 Underlying: Common Stock · 15,528 shares Expires 2036-06-29 F4 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. Read SEC document
June 30, 2026 Filed Jul 2, 2026 22:22 UTC	ALUMIS INC. ALMS · Entity 4816	GrantCommon Stock	3,553	$0.00	$0.00	Disclosure SEC source: 0001253170-26-000011 · form4-07022026_100705.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,553 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:09 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantDirector stock option (right to buy) · Derivative	6,000	$35.08 Strike: $35.08	$210,480.00	Disclosure SEC source: 0001253170-26-000008 · wk-form4_1782763791.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,983 Underlying: Class A Common Stock · 6,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:48 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	4,310	$0.00 Strike: $45.33	$0.00	Disclosure SEC source: 0001104659-26-071422 · tm2617049-1_4seq1.xml · derivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2036-06-04 F5 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:48 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	6,839	$0.00	$0.00	Disclosure SEC source: 0001104659-26-071422 · tm2617049-1_4seq1.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,971 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 21,132 shares of common stock and 6,839 RSUs. Read SEC document
June 03, 2026 Filed Jun 4, 2026 20:25 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $4.72	$0.00	Disclosure SEC source: 0001193125-26-257471 · ownership.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	4,471	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital Partners, L.P. Disclosed balance after: 19,408 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F8 · ownership.nature: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	14,937	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital GP, LLC Disclosed balance after: 14,937 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F7 · ownership.nature: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	66,906	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 10,657,028 F3 · kind: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4 · balance_after: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5 · ownership.nature: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	PurchaseCommon Stock	244,300	$4.83	$1,179,969.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,224,147 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. Read SEC document
February 19, 2026 Filed Feb 21, 2026 00:47 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	GrantStock Option · Derivative	8,300	$0.00 Strike: $28.06	$0.00	Disclosure SEC source: 0001933414-26-000040 · wk-form4_1771634828.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F3 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document
February 19, 2026 Filed Feb 21, 2026 00:47 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	GrantCommon Stock	6,200	$0.00	$0.00	Disclosure SEC source: 0001933414-26-000040 · wk-form4_1771634828.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Read SEC document
January 09, 2026 Filed Jan 13, 2026 23:20 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	588,235	$17.00	$9,999,995.00	Disclosure SEC source: 0001253170-26-000004 · form4-01132026_110101.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,853,488 F1 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 22, 2025 Filed Dec 22, 2025 21:15 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantCommon Stock	1,500,000	$10.00	$15,000,000.00	Disclosure SEC source: 0001231919-25-000652 · form4-12222025_091234.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,500,000 F1 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Samsara Opportunity GP and Dr. Akkaraju have voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
December 18, 2025 Filed Feb 18, 2026 01:15 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	PurchaseCommon Stock	479,847	$10.42	$5,000,005.74	Disclosure SEC source: 0001231919-26-000166 · form4-02182026_010226.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,979,847 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · balance_after: Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby. F3 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 12, 2025 Filed Dec 17, 2025 02:07 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	OtherWarrants to Purchase Common Stock · Derivative	1,064,804	$0.00 Strike: $7.35	$0.00	Disclosure SEC source: 0001253170-25-000025 · form4-12172025_021252.xml · derivative · entry 6 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital LP Disclosed balance after: 0 Underlying: Common Stock · 1,064,804 shares Expires 2025-12-31 F5 · ownership.nature: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 12, 2025 Filed Dec 17, 2025 02:07 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	OtherCommon Stock	1,064,804	$7.35	$7,826,309.40	Disclosure SEC source: 0001253170-25-000025 · form4-12172025_021252.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 6,367,614 F5 · ownership.nature: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 05, 2025 Filed Dec 10, 2025 00:13 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	51,380	$10.73	$551,307.40	Disclosure SEC source: 0001253170-25-000021 · form4-12102025_121251.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,265,253 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.48 to $11.005 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 05, 2025 Filed Dec 10, 2025 00:13 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	70,028	$10.01	$700,980.28	Disclosure SEC source: 0001253170-25-000021 · form4-12102025_121251.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,213,873 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 05, 2025 Filed Dec 10, 2025 00:13 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	64,969	$8.95	$581,472.55	Disclosure SEC source: 0001253170-25-000021 · form4-12102025_121251.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,143,845 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.48 to $9.4793 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 04, 2025 Filed Dec 5, 2025 01:11 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	66,027	$8.18	$540,100.86	Disclosure SEC source: 0001253170-25-000019 · form4-12052025_011232.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,078,876 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.65 to $8.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 03, 2025 Filed Dec 5, 2025 01:11 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	100,000	$7.75	$775,000.00	Disclosure SEC source: 0001253170-25-000019 · form4-12052025_011232.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,012,849 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.41 to $7.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 02, 2025 Filed Dec 5, 2025 01:11 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	96,000	$7.55	$724,800.00	Disclosure SEC source: 0001253170-25-000019 · form4-12052025_011232.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 912,849 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.41 to $7.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
December 01, 2025 Filed Dec 1, 2025 23:09 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	86,350	$7.46	$644,171.00	Disclosure SEC source: 0001253170-25-000017 · form4-12012025_111227.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 816,849 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.31 to $7.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 28, 2025 Filed Dec 1, 2025 23:09 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	38,702	$7.64	$295,683.28	Disclosure SEC source: 0001253170-25-000017 · form4-12012025_111227.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 730,499 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.56 to $7.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 26, 2025 Filed Dec 1, 2025 23:09 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	48,537	$7.64	$370,822.68	Disclosure SEC source: 0001253170-25-000017 · form4-12012025_111227.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 691,797 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.46 to $7.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 20, 2025 Filed Nov 24, 2025 23:50 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	125,743	$7.20	$905,349.60	Disclosure SEC source: 0001253170-25-000014 · form4-11242025_111119.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 643,260 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.92 to $7.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 19, 2025 Filed Nov 20, 2025 01:46 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	137,772	$6.56	$903,784.32	Disclosure SEC source: 0001253170-25-000011 · form4-11202025_011127.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 517,517 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.23 to $6.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 18, 2025 Filed Nov 20, 2025 01:46 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	102,652	$6.05	$621,044.60	Disclosure SEC source: 0001253170-25-000011 · form4-11202025_011127.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 379,745 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.72 to $6.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 17, 2025 Filed Nov 20, 2025 01:46 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	914	$5.51	$5,036.14	Disclosure SEC source: 0001253170-25-000011 · form4-11202025_011127.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 277,093 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.51 to $5.52 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
November 13, 2025 Filed Nov 17, 2025 21:59 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	276,179	$5.25	$1,449,939.75	Disclosure SEC source: 0001253170-25-000008 · form4-11172025_091156.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 276,179 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 07, 2025 Filed Dec 17, 2025 02:07 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	4,403	$40.97	$180,390.91	Disclosure SEC source: 0001253170-25-000025 · form4-12172025_021252.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 530,038 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $40.87 to $41.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 07, 2025 Filed Dec 17, 2025 02:07 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	12,400	$40.18	$498,232.00	Disclosure SEC source: 0001253170-25-000025 · form4-12172025_021252.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 525,635 F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $39.8512 to $40.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 07, 2025 Filed Dec 17, 2025 02:07 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	12,796	$39.31	$503,010.76	Disclosure SEC source: 0001253170-25-000025 · form4-12172025_021252.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 513,235 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $38.85 to $39.849 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 06, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	13,748	$39.52	$543,320.96	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 6 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 500,439 F7 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $39.23 to $39.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 06, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	80,863	$38.68	$3,127,780.84	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 5 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 486,691 F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $38.23 to $39.2298 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 06, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	18,414	$37.89	$697,706.46	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 405,828 F5 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $37.23 to $38.2276 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. Read SEC document
October 03, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	319,700	$37.42	$11,963,174.00	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 387,414 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $37.14 to $37.6227 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 03, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	56,703	$36.74	$2,083,268.22	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 67,714 F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $36.14 to $37.1391 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
October 03, 2025 Filed Oct 8, 2025 00:59 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	11,011	$35.61	$392,101.71	Disclosure SEC source: 0001253170-25-000006 · form4-10082025_121015.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 11,011 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $35.14 to $36.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 22, 2025 Filed Sep 25, 2025 21:04 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantWarrant (Right to Buy) · Derivative	983,214	Not disclosed Strike: $22.71	Not disclosed	Disclosure SEC source: 0001231919-25-000247 · form4-09252025_090918.xml · derivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 983,214 Underlying: Class A Common Stock · 983,214 shares Expires not disclosed F1 · kind: On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. F1 · price: On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. F5 · derivative.exercise_date: The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F5 · derivative.expiration_date: The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 22, 2025 Filed Sep 25, 2025 21:04 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantPre-Funded Warrants (Right to Buy) · Derivative	877,214	Not disclosed Strike: $0.01	Not disclosed	Disclosure SEC source: 0001231919-25-000247 · form4-09252025_090918.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 877,214 Underlying: Class A Common Stock · 877,214 shares Expires not disclosed F1 · kind: On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. F1 · price: On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. F4 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F4 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 22, 2025 Filed Sep 25, 2025 21:04 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantClass A Common Stock	106,000	$15.27	$1,618,090.00	Disclosure SEC source: 0001231919-25-000247 · form4-09252025_090918.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 106,000 F1 · kind: On August 29, 2025, Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") entered into a securities purchase agreement with the Issuer pursuant to which Samsara Opportunity Fund purchased 106,000 shares of the Issuer's Class A Common Stock; pre-funded warrants exercisable for up to 877,214 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 983,214 shares of the Issuer's Class A Common Stock. The transaction closed on September 22, 2025. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
September 04, 2025 Filed Sep 9, 2025 00:07 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	PurchaseCommon Stock	588,235	$25.50	$14,999,992.50	Disclosure SEC source: 0001415889-25-023919 · form4-09092025_120910.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 588,235 F1 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opp LP"). Samsara Opportunity Fund GP, LLC ("Samsara Opp GP") is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. The Reporting Person has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.